New cancers can develop after a stem cell transplant using your own (autologous) or donor (allogeneic) stem cells. This presentation describes what types of cancers may develop, risk factors and what you can do to reduce your risk of developing a secondary cancer,

People who undergo a stem cell transplant or CAR T-cell therapy have an increased risk of infection after treatment. This presentation discusses who’s at risk, when infections typically arise, steps taken by transplant teams to avoid and treat infections and steps patients can take to reduce their risk of developing a serious infection.

Graft versus Host Disease (GVHD) is a common complication after allogeneic stem cell transplant. Learn the difference between acute and chronic GVHD and how each develops. Both standard therapies and exciting new prevention and treatment interventions are discussed.

Caregivers are critical to the United States (US) Health Care system as more procedures are moved outpatient and home care is required. Yet they must deal with the emotional toll of the responsibilities, the financial impact of being a caregiver and the accompanying negative emotions. Often times, caregivers are required to perform tasks previously performed by medical professionals yet caregivers don’t necessarily have the training. Just like the cancer patients, caregivers experience a whole range of negative emotions which need to be acknowledged and addressed.

What you eat can significantly impact recovery after transplant and CAR T-cell therapy. This presentation discusses the nutritional needs of stem cell transplant and CAR T-cell recipients in the short- and long-term; how food choices affect organ function and help prevent complications; how to manage eating difficulties; the role of prebiotics and probiotic in nutrition; and common myths about the relationship between cancer and nutrition.

The overall health of the gut microbiome and its organisms can influence the prevalence and severity of graft-versus-host disease. This presentation reviews the causes and mechanisms of how organisms in the gut can affect GVHD and reviews potential strategies to minimize this problem.

Un microbioma intestinal (los microorganismos que viven en el intestino) diverso es esencial para una buena salud. Lo que come puede determinar qué tan saludable es su microbioma intestinal.

Multiple studies have shown that most patients who receive chimeric antigen receptor (CAR) T-cell therapy report a good quality of life long-term. Learn how CAR T-cell therapy is performed and its short-term and long-term effects on patients and caregivers. Discover key differences between CAR T-cell, stem cell transplant and other and chemotherapy treatments.

Los cánceres de sangre que se presentan con mayor frecuencia en adultos mayores se pueden tratar con un trasplante de médula ósea o células madre o con terapia de células CAR T. Sin embargo, a menudo no se les ofrecen estos tratamientos. Conozca por qué esto debería cambiar.

Para los pacientes que han recaído después del tratamiento estándar para el linfoma, la terapia con células CAR T puede ser un tratamiento eficaz.